Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Bio Sequence
2 min read
Choose A Reliable Biological Sequence Database for Large Molecule Drug's FTO
14 September 2023
Research and development (R&D) efforts in biopharmaceuticals are high, cycles are long, and risks are significant. Companies in this industry heavily rely on core technologies, specialized talents, and intellectual property protection. Drug patents' freedom to operate (FTO) is crucial for determining whether drug candidates can be further commercialized.
Drug Insights
4 min read
A Comprehensive Review of Febuxostat's R&D Innovations
13 September 2023
This article summarized the latest R&D progress of Febuxostat, the Mechanism of Action for Febuxostat, and the drug target R&D trends for Febuxostat.
Latest Hotspot
4 min read
Chia Tai Tianqing Pharmaceutical initiates global multicenter phase III clinical trials for the pan-PPAR agonist Lanifibranor
13 September 2023
On Sept 11, 2023, Chia Tai Tianqing Pharmaceutical launched a global phase III trial, evaluating Lanifibranor's efficacy and safety in adult NASH patients with stage 2/3 hepatic fibrosis, excluding cirrhosis.
Drug Insights
4 min read
Pharmaceutical Insights: Exemestane's R&D Progress and its Mechanism of Action on Drug Target
13 September 2023
This article summarized the latest R&D progress of Exemestane, the Mechanism of Action for Exemestane, and the drug target R&D trends for Exemestane.
Valuable Targets
5 min read
Understanding the Development Progress of JAK2 Inhibitor
13 September 2023
JAK2 (Janus kinase 2) is an enzyme that plays a crucial role in the human body, particularly in the regulation of cell growth and differentiation.
Drug Insights
4 min read
Exploring Etomidate's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
13 September 2023
This article summarized the latest R&D progress of Etomidate, the Mechanism of Action for Etomidate, and the drug target R&D trends for Etomidate.
Latest Hotspot
3 min read
Abbisko Therapeutics' CSF-1R Inhibitor, Pimicotinib, Approved for Global Multicenter Phase 3 Clinical Trials in Europe
13 September 2023
On September 11, 2023, Abbisko Therapeutics announced that its innovative CSF-1R inhibitor pimicotinib (ABSK021) was approved by the European Medicines Agency.
Drug Insights
4 min read
Decoding Droperidol: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
13 September 2023
This article summarized the latest R&D progress of Droperidol, the Mechanism of Action for Droperidol, and the drug target R&D trends for Droperidol.
Bio Sequence
2 min read
Ways to Evaluate the Worldwide R&D Progress of Our Study Sequence
13 September 2023
The progress of R&D efforts in a life-science area of study can greatly affect the likelihood of breakthroughs and advancements. So, how do we analyze the global research and development progress of the sequence we are studying? I recommend that you use the Patsnap Bio Sequence Database to query data and information.
Drug Insights
4 min read
Deep Scientific Insights on Dofetilide's R&D Progress
13 September 2023
This article summarized the latest R&D progress of Dofetilide, the Mechanism of Action for Dofetilide, and the drug target R&D trends for Dofetilide.
Latest Hotspot
3 min read
Phanes Therapeutics reports its first patient has been administered with PT217 in a Phase 1 trial
13 September 2023
Biotech firm, Phanes Therapeutics, has announced its Phase 1 clinical trial of PT217, a first-in-class drug targeting DLL3 and CD47 in small cell lung cancer. The trial uses a new IgG-like bispecific antibody and the first patient has been treated.
Drug Insights
4 min read
An In-depth Analysis of Divalproex sodium's R&D Progress
13 September 2023
This article summarized the latest R&D progress of Divalproex sodium, the Mechanism of Action for Divalproex sodium, and the drug target R&D trends for Divalproex sodium.